Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
In this article, the effectiveness of a multi-targeted chemo-switch (C-S) schedule that combines metronomic chemotherapy (MET) after treatment with the maximum tolerated dose (MTD) is reported. This schedule was tested with gemcitabine in two distinct human pancreatic adenocarcinoma orthotopic model...
| Authors: | ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Accepted version |
| Publication date: | 2013 |
| Country: | España |
| Institution: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repository: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:2445/120265 |
| Online Access: | https://hdl.handle.net/2445/120265 |
| Access Level: | Open access |
| Keyword: | Quimioteràpia del càncer Medicaments antineoplàstics Angiogènesi Cèl·lules mare Cèl·lules canceroses Cancer chemotherapy Antineoplastic agents Neovascularization Stem cells Cancer cells |
| _version_ | 1878741124474994688 |
|---|---|
| author | Vives, Marta |
| author2 | Ginestà, Mireia M. Gracova, Kristina Graupera i Garcia-Milà, Mariona Casanovas i Casanovas, Oriol Capellá, G. (Gabriel) Serrano Piñol, M. Teresa Laquente, Berta Viñals Canals, Francesc |
| author2_role | author author author author author author author author |
| author_browse | Capellá, G. (Gabriel) Casanovas i Casanovas, Oriol Ginestà, Mireia M. Gracova, Kristina Graupera i Garcia-Milà, Mariona Laquente, Berta Serrano Piñol, M. Teresa Vives, Marta Viñals Canals, Francesc |
| author_facet | Vives, Marta Ginestà, Mireia M. Gracova, Kristina Graupera i Garcia-Milà, Mariona Casanovas i Casanovas, Oriol Capellá, G. (Gabriel) Serrano Piñol, M. Teresa Laquente, Berta Viñals Canals, Francesc |
| author_role | author |
| collection | Recercat. Dipósit de la Recerca de Catalunya |
| description | In this article, the effectiveness of a multi-targeted chemo-switch (C-S) schedule that combines metronomic chemotherapy (MET) after treatment with the maximum tolerated dose (MTD) is reported. This schedule was tested with gemcitabine in two distinct human pancreatic adenocarcinoma orthotopic models and with cyclophosphamide in an orthotopic ovarian cancer model. In both models, the C-S schedule had the most favourable effect, achieving at least 80% tumour growth inhibition without increased toxicity. Moreover, in the pancreatic cancer model, although peritoneal metastases were observed in control and MTD groups, no dissemination was observed in the MET and C-S groups. C-S treatment caused a decrease in angiogenesis, and its effect on tumour growth was similar to that produced by the MTD followed by anti-angiogenic DC101 treatment. C-S treatment combined an increase in thrombospondin-1 expression with a decrease in the number of CD133+ cancer cells and triple-positive CD133+/CD44+/CD24+ cancer stem cells (CSCs). These findings confirm that the C-S schedule is a challenging clinical strategy with demonstrable inhibitory effects on tumour dissemination, angiogenesis and CSCs. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_df8feb9f7b8e47b8d3d2c58bc9c1cd53 |
| institution | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:recercat.cat:2445/120265 |
| publishDate | 2013 |
| publishDateSort | 2013 |
| publisher | Wiley |
| publisherStr | Wiley |
| reponame_str | Recercat. Dipósit de la Recerca de Catalunya |
| spelling | Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells Vives, Marta Ginestà, Mireia M. Gracova, Kristina Graupera i Garcia-Milà, Mariona Casanovas i Casanovas, Oriol Capellá, G. (Gabriel) Serrano Piñol, M. Teresa Laquente, Berta Viñals Canals, Francesc Quimioteràpia del càncer Medicaments antineoplàstics Angiogènesi Cèl·lules mare Cèl·lules canceroses Cancer chemotherapy Antineoplastic agents Neovascularization Stem cells Cancer cells In this article, the effectiveness of a multi-targeted chemo-switch (C-S) schedule that combines metronomic chemotherapy (MET) after treatment with the maximum tolerated dose (MTD) is reported. This schedule was tested with gemcitabine in two distinct human pancreatic adenocarcinoma orthotopic models and with cyclophosphamide in an orthotopic ovarian cancer model. In both models, the C-S schedule had the most favourable effect, achieving at least 80% tumour growth inhibition without increased toxicity. Moreover, in the pancreatic cancer model, although peritoneal metastases were observed in control and MTD groups, no dissemination was observed in the MET and C-S groups. C-S treatment caused a decrease in angiogenesis, and its effect on tumour growth was similar to that produced by the MTD followed by anti-angiogenic DC101 treatment. C-S treatment combined an increase in thrombospondin-1 expression with a decrease in the number of CD133+ cancer cells and triple-positive CD133+/CD44+/CD24+ cancer stem cells (CSCs). These findings confirm that the C-S schedule is a challenging clinical strategy with demonstrable inhibitory effects on tumour dissemination, angiogenesis and CSCs. Wiley https://hdl.handle.net/2445/120265 |
| spellingShingle | Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells Vives, Marta Quimioteràpia del càncer Medicaments antineoplàstics Angiogènesi Cèl·lules mare Cèl·lules canceroses Cancer chemotherapy Antineoplastic agents Neovascularization Stem cells Cancer cells |
| status_str | acceptedVersion |
| title | Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells |
| title_full | Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells |
| title_fullStr | Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells |
| title_full_unstemmed | Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells |
| title_short | Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells |
| title_sort | Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells |
| topic | Quimioteràpia del càncer Medicaments antineoplàstics Angiogènesi Cèl·lules mare Cèl·lules canceroses Cancer chemotherapy Antineoplastic agents Neovascularization Stem cells Cancer cells |
| topic_facet | Quimioteràpia del càncer Medicaments antineoplàstics Angiogènesi Cèl·lules mare Cèl·lules canceroses Cancer chemotherapy Antineoplastic agents Neovascularization Stem cells Cancer cells |
| url | https://hdl.handle.net/2445/120265 |